IceCure Medical Regains Nasdaq Compliance Following Reverse Stock Split
Summary
IceCure Medical has officially regained compliance with Nasdaq's minimum bid price requirement, receiving notice on June 18th. This positive development follows the 1-for-30 reverse stock split that became effective on June 4th, which was implemented to address the prior non-compliance. The company's shares maintained a bid price above $1.00 for 10 consecutive business days, successfully resolving the delisting threat. This removes a significant risk factor and ensures the company's continued listing on Nasdaq.
At the time of this announcement, ICCM was trading at $8.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.1M. The 52-week trading range was $2.12 to $42.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.